• Safety endpoint of subjects free from specified adverse events [ Time Frame: 4 weeks after placement of WRAPSODY stent graft ]
  The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure.
• Effectiveness endpoint of subjects with improvement of Rutherford Category [ Time Frame: 4 weeks after placement of WRAPSODY stent graft ]
  The primary clinical effectiveness endpoint is the proportion of subjects with improvement of at least 1 Rutherford category within 4 weeks of the index procedure. Composite with Outcome 3.
• Effectiveness endpoint of subjects with patency [ Time Frame: 4 weeks after placement of WRAPSODY stent graft ]
  The primary clinical effectiveness endpoint is the proportion of subjects with patency as evaluated by duplex ultrasound at 4 weeks after index procedure. Composite with Outcome 2.

• Primary Safety Endpoint [ Time Frame: 4 weeks after placement of WRAPSODY stent graft ]
  The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure.
• Primary Efficacy Endpoint 1 [ Time Frame: 4 weeks after placement of WRAPSODY stent graft ]
  The primary clinical effectiveness endpoint is the proportion of subjects with improvement of at least 1 Rutherford category.
• Primary Efficacy Endpoint 2 [ Time Frame: 4 weeks after placement of WRAPSODY stent graft ]
  The primary clinical effectiveness endpoint is the proportion of subjects with patency as evaluated by duplex ultrasound at 4 weeks after index procedure.

Approximately 30 subjects will be enrolled. Post study procedure subjects will have planned follow-up visits at 4 weeks, 24, 36 and 52 weeks, and unscheduled visits as medically necessary,

The primary study safety endpoint is the proportion of subjects free from a composite of device- or procedure-related death, myocardial infarction, or amputation above the metatarsals in the treated leg resulting from a vascular event, or device- or procedure-related serious adverse events within 4 weeks of the index procedure. The primary clinical effectiveness endpoint is the proportion of subjects with a composite improvement of at least 1 Rutherford category and patency as evaluated by duplex ultrasound at 4 weeks after index procedure.

• Stenosis of Artery
• Peripheral Arterial Disease
• Iliac Artery Disease
• Iliac Artery Occlusion

Inclusion Criteria:

1. Subject has signed informed consent
2. Subject is ≥ 21 years of age
3. Subject is able and willing to comply with study requirements
4. Male, infertile female, or female practicing contraception and a negative pregnancy test within 7 days prior to the study procedure
5. Symptomatic claudication or rest pain without tissue loss, Rutherford category 2-4
6. Angiographic evidence of de novo or restenotic target lesion(s) in native vessels in the common and/or external iliac artery(ies) (multiple stenoses may exist within the target lesion)
7. Total lesion(s) length is ≤ 110mm
8. Target lesion(s) is at least 3 cm from an existing stent or stent graft
9. At least 1 stenosis in the target vessel has ≥ 50% stenosis
10. Target vessel diameter is between 4.6 and 14.4mm at angiographic screening for device placement
11. Adequate ipsilateral blood flow, including at least 1 patent (<50% stenotic) superficial femoral or profundal femoral artery
12. Full expansion of an appropriately sized (in the investigator's opinion) standard angioplasty balloon has been achieved during primary angioplasty at the target lesion prior to enrollment

Exclusion Criteria:

1. Subject has undergone an intervention (surgical or percutaneous) in the target limb(s) <30 days from the date of the index study procedure
2. Subject has a surgical or percutaneous procedure in the target limb(s) planned within 30 days following the index study procedure
3. Previous or planned bypass surgery in the target limb(s)
4. Coronary intervention within 30 days prior to enrollment or planned within 12 months after index study procedure
5. Subject has had a stroke within 90 days prior to the index study procedure
6. Subject has had a transient ischemic attack within 30 days prior to the index study procedure
7. Uncorrectable coagulation disorder
8. Subject cannot receive heparin, dual antiplatelet treatment, or anticoagulant(s) appropriate in the opinion of the investigator
9. Condition unrelated to study anticipated to require indefinite anticoagulation
10. Evidence of blood borne infection
11. Hypersensitivity to nickel titanium alloy
12. Allergy to radiographic contrast material which cannot be adequately premedicated
13. Serum creatinine >2.5mg/dL
14. The subject is enrolled in another investigational study
15. Life expectancy is ≤ 12 months
16. Active malignancy other than non-melanomatous skin cancer
17. Stenosis/restenosis is located within a previously placed stent or stent graft
18. Angiographic evidence of thrombus within or adjacent to the target lesion(s)
19. Aneurysmal dilation proximal or distal to the target lesion(s) that could interfere with placement of the study device
20. Abdominal aortic artery stent, if it could interfere with placement of the study device
21. Target lesion(s) are located such that the stent graft would prevent blood flow to the internal iliac artery, if patent
22. Lesions requiring atherectomy or ablation to facilitate stent graft delivery
23. Any other condition deemed exclusionary in the opinion of the investigator for documented reasons relating to the health and/or welfare of the subject